Ciprofloxacin as a QTc prolonging drug in the G-Standaard: processing of the interaction signal in practice OBJECTIVE To analyse the effect of the introduction of an interaction signal when ordering ciprofloxacin concomitantly with another QTc prolonging drug on the number of stopped orders and the number of ECGs measured. Ciprofloxacin has been added to the G-Standaard as a QTc prolonging drug with a known risk of torsade de pointes (TdP). DESIGN Observational retrospective cohort study. METHODS All inpatient orders for ciprofloxacin, concomitantly pre-scribed with another QTc prolonging drug in the Spaarne Hospital (Haarlem/Hoofddorp) were selected. The study included a period before introduction of ciprofloxacin as QTc prolonging drug (March 29 until June 1, 2015). and a period thereafter (June 1 until November U. 20151. We compared how often preservers stopped an order for a QTc prolonging drug and how often ECGs were measured before and after start of the QTc prolonging drug-drug combination. RESULTS Ciprofloxacin generated 4.2 QTc interaction signals per day. which was an increase of 22.3% for the total number of QTc interaction signals. In 9.4% of the QTc interaction signals with ciprofloxacin, one or more of the QTc prolonging drugs were stopped. The number of ECGs taken within seven days before and three days after start of the combination with ciprofloxacin increased by respectively 8.7% IP ▪ 0.008) and 7 0% IP = 0.021). CONCLUSION The introduction of the QTc interaction signal for ciprofloxacin has a clear effect in the Spaarne hospital.
Pharmaceutisch Weekblad
Erasmus MC: University Medical Center Rotterdam

Woldman, E. (Evelien), Berger, F., van den Bemt, P., Van Den Hoeven, R. (Ruud), & Becker, M. (2016). Ciprofloxacine als QTc-verlenger in de G-Standaard: Afhandeling van het interactiesignaal in de praktijk. Pharmaceutisch Weekblad, 151(50), 25–29. Retrieved from